A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 mcg as needed compared with Pulmicort (budesonide) Turbuhaler 200 mcg twice daily plus terbutaline Turbuhaler 0.4 mg as needed

Trial Profile

A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 mcg as needed compared with Pulmicort (budesonide) Turbuhaler 200 mcg twice daily plus terbutaline Turbuhaler 0.4 mg as needed

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Terbutaline
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SYGMA 2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2017 Trial has been completed in Spain (End date: 2017-08-16).
    • 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top